PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lumasiran→

Lumasiran PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1834610-13-7
Molecular formula
C530H712F10N173O320P43S6
Molecular weight
16340.63 g/mol
Drug class
Hydroxyacid oxidase 1 (HAO1) gene-directed small interfering RNA (siRNA)RNA interference therapy
Mechanism of action
A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RISC-mediated degradation of HAO1 mRNA, reducing hepatic glycolate oxidase and decreasing glyoxylate and oxalate production.
Indications / reported uses
  • Treatment of primary hyperoxaluria type 1 (PH1) in adults and paediatric patients to reduce urinary and plasma oxalate; dosing and use depend on age, weight and kidney function under the product label

Sources: US DailyMed — OXLUMO (lumasiran) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Lumasiran PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lumasiran Permitted Daily Exposure (PDE) report (the Lumasiran PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lumasiran Occupational Exposure Limit (OEL) report (the Lumasiran OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.